nm23 as a prognostic marker in primary cutaneous melanoma: Evaluation using tissue microarray in a patient group with long-term follow-up

Melanoma Research

Volumn 15, Issue 5, 2005, Pages 435-440

  Pacifico, Marc D ^a   Grover, Rajiv ^a   Richman, Paul I ^a   Buffa, Francesca ^a   Daley, Frances M ^a   Wilson, George D ^b  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Melanoma; nm23; Prognosis; Tissue microarray

Indexed keywords

PROTEIN NM23; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE MARKER; DNA MICROARRAY; FEMALE; FOLLOW UP; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MELANOMA; MIDDLE AGED; NUCLEOSIDE-DIPHOSPHATE KINASE; PARAFFIN EMBEDDING; PROGNOSIS; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 27644580708     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200510000-00012     Document Type: Article

References (21)

1. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reinigen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622-3634.
2. Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002; 147:62-70.
3. Leone A, Flatow U, King CR, Sandeen MA, Margulies IM, Liotta LA, et al. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell 1991; 65:25-35.
4. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988; 80:200-204.
5. Nakayama T, Ohtsuru A, Nakao K, Shima M, Nakata K, Watanabe K, et al. Expression in human hepatocellular carcinoma of nucleoside diphosphate kinase, a homologue of the nm23 gene product. J Natl Cancer Inst 1992; 84:1349-1354.
6. Huwer H, Engel M, Welter C, Dooley S, Kalweit G, Feindt P, et al. Squamous cell carcinoma of the lung: does the nm23 gene expression correlate to the tumor stage? Thorac Cardiovasc Surg 1994; 42:298-301.
7. Florenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS, Fodstad O. Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression. Cancer Res 1992; 52:6088-6091.
8. Xerri L, Grab JJ, Battyani Z, Gouvernet J, Hassoun J, Bonerandi JJ. nm23 expression in metastasis of malignant melanoma is a predictive prognostic parameter correlated with survival. Br J Cancer 1994; 70:1224-1228.
9. Holmes SC, MacKie RM. The value of nm23 expression as an independent prognostic indicator in primary thick melanoma. J Cutan Pathol 1996; 23:344-349.
10. Saitoh K, Takahashi H, Yamamoto M, Kishi H, Parsons PG. Expression of metastasis suppressor gene product, nm23 protein, is not inversely correlated with the tumour progression in human malignant melanomas. Histopathology 1996; 29:497-505.
11. Reichrath J, Seyfried P, Braun R, Muller SM, Baum HP, Bahmer FA. Expression of nm23 protein in acquired melanocytic nevi, malignant melanoma and metastases of malignant melanoma: an immunohistological assessment in human skin. Dermatology 1997; 194:136-139.
12. Easty DJ, Maung K, Lascu I, Veron M, Fallowfield ME, Hart IR, et al. Expression of nm23 in human melanoma progression and metastasis. Br J Cancer 1996; 74:109-114.
13. McDermott NC, Milburn C, Curran B, Kay EW, Barry Walsh C, Leader MB. Immunohistochemical expression of nm23 in primary invasive malignant melanoma is predictive of survival outcome. J Pathol 2000; 190:157-162.
14. Dome B, Somlai B, Timar J. The loss of nm23 protein in malignant melanoma predicts lymphatic spread without affecting survival. Anticancer Res 2000; 20:3971-3974.
15. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4:844-847.
16. Pacifico MD, Graver R, Richman P, Daley F, Wilson GD. Validation of tissue microarray for the immunohistochemical profiling of melanoma. Melanoma Res 2004; 14:39-42.
17. Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999; 5:1966-1975.
18. Kimura N, Shimada N, Ishijima Y, Fukuda M, Takagi Y, Ishikawa N. Nucleoside diphosphate kinases in mammalian signal transduction systems: recent development and perspective. J Bioenerg Biomembr 2003; 35:41-47.
19. Parhar RS, Shi Y, Zou M, Farid NR, Ernst P, al-Sedairy ST. Effects of cytokine-mediated modulation of nm23 expression on the invasion and metastatic behavior of B16F10 melanoma cells. Int J Cancer 1995; 60:204-210.
20. Lee CS, Pirdas A, Lee MW. Immunohistochemical demonstration of the nm23-H1 gene product in human malignant melanoma and Spitz nevi. Pathology 1996; 28:220-224.
21. van den Oord JJ, Maes A, Stas M, Nuyts J, De Wever I, De Wolf-Peeters C. Prognostic significance of nm23 protein expression in malignant melanoma. An immunohistochemical study. Melanoma Res 1997; 7:121-128.